Autolus Therapeutics plc (NASDAQ:AUTL) Shares Bought by Great Point Partners LLC

Great Point Partners LLC raised its position in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 195.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,441,667 shares of the company's stock after acquiring an additional 2,275,000 shares during the quarter. Autolus Therapeutics accounts for about 2.3% of Great Point Partners LLC's investment portfolio, making the stock its 21st largest holding. Great Point Partners LLC owned approximately 1.29% of Autolus Therapeutics worth $11,977,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the company. Wealth Effects LLC grew its holdings in Autolus Therapeutics by 19.5% during the 2nd quarter. Wealth Effects LLC now owns 49,000 shares of the company's stock valued at $171,000 after purchasing an additional 8,000 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Autolus Therapeutics by 66.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 27,034 shares of the company's stock worth $172,000 after acquiring an additional 10,771 shares during the last quarter. EntryPoint Capital LLC boosted its holdings in Autolus Therapeutics by 113.6% in the first quarter. EntryPoint Capital LLC now owns 21,540 shares of the company's stock valued at $137,000 after purchasing an additional 11,456 shares during the last quarter. ProShare Advisors LLC acquired a new stake in Autolus Therapeutics during the 2nd quarter valued at approximately $43,000. Finally, Privium Fund Management B.V. increased its holdings in Autolus Therapeutics by 43.2% during the 1st quarter. Privium Fund Management B.V. now owns 50,058 shares of the company's stock worth $319,000 after purchasing an additional 15,091 shares during the last quarter. 72.83% of the stock is owned by institutional investors and hedge funds.

Autolus Therapeutics Stock Performance

AUTL stock traded up $0.01 during midday trading on Tuesday, reaching $3.51. The company had a trading volume of 522,771 shares, compared to its average volume of 1,399,861. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09. The stock has a 50 day moving average price of $4.07 and a 200 day moving average price of $4.37. The firm has a market capitalization of $933.79 million, a PE ratio of -2.92 and a beta of 2.05. Autolus Therapeutics plc has a fifty-two week low of $2.01 and a fifty-two week high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.03). Analysts anticipate that Autolus Therapeutics plc will post -0.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on AUTL shares. Needham & Company LLC reissued a "buy" rating and issued a $9.00 target price on shares of Autolus Therapeutics in a research report on Monday, June 17th. William Blair reiterated an "outperform" rating on shares of Autolus Therapeutics in a research report on Monday, June 3rd. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, Autolus Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $8.70.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.